Aldose reductase (AR) reduces cytotoxic aldehydes and glutathione conjugates of aldehydes derived from lipid peroxidation. Its inhibition has been shown to increase oxidative injury and abolish the late phase of ischemic preconditioning. However, the mechanisms by which ischemia regulates AR activity remain unclear. Herein, we report that rat hearts subjected to ischemia, in situ or ex vivo, display a 2-4-fold increase in AR activity. The AR activity was not further enhanced by reperfusion. Activation increased V max of the enzyme without affecting the K m and decreased the sensitivity of the enzyme to inhibition by sorbinil. Enzyme activation could be prevented by pretreating the hearts with the radical scavenging thiol, N-(2-mercaptoproprionyl)glycine or the superoxide dismutase mimetic, Tiron, or by treating homogenates with dithiothreitol. In vitro, the recombinant enzyme was activated upon treatment with H 2 O 2 and the activated, but not the native enzyme, formed a covalent adduct with the sulfenic acid-specific reagent dimedone. The enzyme activity in the ischemic, but not the nonischemic heart homogenates was inhibited by dimedone. Separation of proteins from hearts subjected to coronary occlusion by twodimensional electrophoresis and subsequent matrix-assisted laser desorption ionization time-of-flight/mass spectrometry analysis revealed the formation of sulfenic acids at Cys-298 and Cys-303. These data indicate that reactive oxygen species formed in the ischemic heart activate AR by modifying its cysteine residues to sulfenic acids.
Aldose reductase (AR)2 is an efficient catalyst for the reduction of glucose and a wide range of aldehydes derived from lipid peroxidation (1, 2). The enzyme also catalyzes the reduction of glutathione conjugates of unsaturated aldehydes such as acrolein, 4-hydroxy-trans-2-nonenal, and trans-2-hexenal with higher efficiency than the parent aldehyde (3, 4). Our recent studies suggest that AR participates also in the metabolism of 1-palmitoyl-2-oxovaleroyl phosphatidylcholine and related phospholipid ("core") aldehydes (5) generated upon oxidation of unsaturated fatty acids esterified to the sn-2 position of phospholipids. The efficacy of AR in reducing multiple aldehydes suggests that the enzyme may be involved in cellular defense against aldehydes produced by lipid peroxidation. The notion that AR is involved in antioxidant defense is supported by evidence showing that: the AR gene is induced by oxidants such as aldehydes (6, 7) and hydrogen peroxide (7,8) and under conditions associated with oxidative stress such as myocardial ischemia (9), heart failure (10), vascular inflammation (11), and alcoholic liver disease (12); and that inhibition of AR increases aldehyde toxicity in rat vascular smooth muscle cell lines (7) and Chinese hamster fibroblast cell lines (8). An antioxidant role of AR is also in accord with our observation that inhibition of the enzyme increases 4-hydroxytrans-2-nonenal accumulation in the ischemic heart and abolishes cardioprotection associated with ...